Source: Radiology 2001 Jul;220(1):145-9
Percutaneous radio-frequency ablation of liver metastases from
breast cancer: initial experience in 24 patients.
Livraghi T, Goldberg SN, Solbiati L, Meloni F, Ierace T, Gazelle GS.
Department of Radiology, Ospedale Civile, Vimercate, Italy (T.L.,
PURPOSE: To evaluate the authors' initial experience in a consecutive series of 24 patients with breast cancer liver metastases treated with radio-frequency (RF) ablation.
MATERIALS AND METHODS: Twenty-four consecutive patients with 64 metastases
measuring 1.0-6.6 cm in diameter (mean, 1.9 cm) underwent ultrasonography-guided percutaneous RF ablation with 18-gauge, internally cooled electrodes. Treatment was performed with the
patient under conscious sedation and analgesia or general anesthesia. A single lesion was treated in 16 patients, and multiple lesions were treated in eight patients. Follow-up with serial
computed tomography ranged from 4 to 44 months (mean, 10 months; median, 19 months).
RESULTS: Complete necrosis was achieved in 59 (92%) of 64 lesions. Among the 59 lesions, complete necrosis
required a single treatment session in 58 lesions (92%) and two treatment sessions in one lesion (2%). In 14 (58%) of 24
patients, new metastases developed during follow-up. Ten (71%) of these 14 patients developed new liver metastases. Currently, 10 (63%) of 16
patients whose lesions were initially confined to the liver are free of
disease. One patient died of progressive brain metastases. No major complications occurred. Two minor complications were observed.
CONCLUSION: On the basis of preliminary study results, percutaneous RF ablation appears to be a simple, safe, and effective treatment
for focal liver metastases in selected patients with breast cancer.
PMID: 11425987 [PubMed - in process]